

Return on Innovation



Global health R&D delivers for Colorado



US government (USG) investment in global health R&D has delivered

\$93.8 million
to Colorado research institutions*

1,400+ new jobs
for Colorado[†]

Colorado's top global health R&D institutions by USG funding*

| ORGANIZATION | FUNDING |
|---|----------------|
| Colorado State University | \$58.3 million |
| University of Colorado at Denver | \$27.2 million |
| University of Colorado at Boulder | \$5.8 million |
| Precision Photonics Corporation (now part of IDEX Corporation) | \$1.4 million |
| Colorado School of Mines | \$1.0 million |
| Keystone Symposia on Molecular and Cellular Biology | \$88 thousand |

Neglected diseases in Colorado[‡]

| | |
|--------------------|-------|
| HIV diagnoses | 3,491 |
| West Nile cases | 1,083 |
| Tuberculosis cases | 668 |
| Malaria cases | 199 |
| Zika cases | 61 |

Colorado industry in global health R&D

AstraZeneca: Boulder
Endolytics: Fort Collins
Mbio: Boulder
Novartis: Broomfield
Sandoz: Broomfield


Global health R&D at work in the Centennial State



PATH/Patrick McKern

University of Colorado School of Medicine researchers discovered that a process that protects the body from autoimmune disease also blocks the production of antibodies against HIV-1, the most common cause of AIDS. The immune system normally suppresses these antibodies to keep them from targeting healthy tissues; the question now is whether temporarily halting this mechanism would allow generation of antibodies capable of neutralizing HIV-1 without harm to patients. The findings could help scientists develop a vaccine.

Colorado's top areas of global health R&D by USG funding*



GLOBAL HEALTH R&D IS A SMART INVESTMENT FOR THE UNITED STATES[§]

89¢ of every dollar
 the USG invests in global health R&D stays within the United States, **supporting the domestic economy.**

USG investment in global health R&D between 2007 and 2015 **generated an estimated:**

200K new US jobs

\$33 BILLION in US economic growth.

*Authors' analysis of USG investment data from the G-FINDER survey, including funding for R&D for neglected diseases from 2007-2015 and for Ebola and select viral hemorrhagic fevers from 2014-2015. Reflects USG funding received by entities in state including academic and research institutions, product development partnerships, other nonprofits, select corporations, and government research institutions, as well as self-funding or other federal agency transfers received by federal agencies located in state; but excludes pharmaceutical industry data which is aggregated and anonymized in the survey for confidentiality purposes. See www.ghtcoalition.org for full methodology.

[†]Based on previous analysis of the economic impact of National Institutes of Health R&D funding and author's analysis described above. See www.ghtcoalition.org for additional details.
[‡]Centers for Disease Control and Prevention: HIV diagnoses 2008-2016, West Nile virus disease cases 2008-2016, Tuberculosis cases 2008-2016, Malaria cases 2008-2014, Zika virus disease cases 2015-2017.

[§]Source: Policy Cures Research, Global Health Technologies Coalition. Return on innovation: Why global health R&D is a smart investment for the United States. 2017.

[¶]NTD: neglected tropical disease. NTDs include Buruli ulcer, Dengue, Helminths, Kinetoplastids, Leprosy, Trachoma, and Leptospirosis.